Chronic sclerosing sialadenitis

Lore & Background

Chronic sclerosing sialadenitis, also called Küttner's tumor, was first described in 1896 by German surgeon Hermann Küttner, who reported four cases of submandibular gland lesions. The condition is a chronic inflammatory disorder that produces hard, swollen masses clinically indistinguishable from malignant tumors. It is now understood as a manifestation of IgG4-related disease, with abundant IgG4-positive plasma cells infiltrating the glandular tissue. The cause remains uncertain, with proposed factors including sialolithiasis (hard salivary calculi), ductal abnormalities, and autoimmune mechanisms. The condition primarily affects adults aged 40–70, though a case in an 11-year-old boy in Brazil was reported in 2012.

Reader's Guide

Chronic sclerosing sialadenitis is significant because it represents a diagnostic challenge in head and neck pathology. Despite being benign, its clinical presentation—hard, indurated masses—closely mimics salivary gland malignancies, leading to frequent surgical resection for definitive diagnosis. The condition is under-recognized, with an estimated 44% of patients undergoing submandibular resection found to have it. Histologically, it is characterized by lymphoplasmacytic infiltration, reactive lymphoid follicles, acinar atrophy, periductal fibrosis, and sclerosis. Its recognition as part of the IgG4-related disease spectrum has opened avenues for non-surgical treatment, such as steroid therapy, which can shrink lesions and reduce serum IgG4 levels. Pre-operative diagnosis increasingly relies on ultrasonography and fine-needle aspiration cytology, though definitive diagnosis still requires histopathology. The condition's rarity and mimicry of malignancy underscore the importance of awareness among clinicians to avoid unnecessary radical surgery.

Did You Know?

• Küttner's tumor is named after Hermann Küttner, a German oral and maxillofacial surgeon who first reported four cases in 1896.
• The condition is now regarded as a manifestation of IgG4-related disease.
• Approximately 44% of patients undergoing submandibular resection are found to have this condition.
• A case of Küttner's tumor was described in an 11-year-old boy in Brazil in 2012.

The Diagnostic Mimic: When a Benign Lesion Masquerades as Cancer

Chronic sclerosing sialadenitis, most often presenting as a hard, enlarged, and painful mass in the submandibular region, represents one of the most vexing diagnostic puzzles in head and neck medicine. Because the lesion is clinically indistinguishable from a true salivary gland neoplasm, patients are routinely directed toward surgical excision—sialoadenectomy—on the suspicion of malignancy. The benign nature of the condition is typically confirmed only after the excised tissue undergoes histopathological examination. The masses may appear unilaterally or bilaterally, and although the submandibular gland is the predominant site, the parotid and other minor salivary glands can also be affected. The diagnostic stakes are considerable: roughly 20–25% of parotid tumors, 35–40% of submandibular tumors, and over 90% of sublingual tumors are malignant. This persistent ambiguity has kept the condition significantly under-reported, with many cases surfacing only in retrospective pathology reports rather than being recognized at the point of clinical presentation.

Microscopic Architecture: Lymphoplasmacytic Infiltrate and Progressive Fibrosis

Under the microscope, chronic sclerosing sialadenitis reveals a characteristic pattern of tissue destruction and repair that distinguishes it from both neoplasms and lymphoma. The glandular parenchyma is densely infiltrated by activated B-cells, helper T-cells, and plasma cells, collectively termed a lymphoplasmacytic infiltrate, organized around reactive lymphoid follicles that conspicuously lack the atypical cells hallmark of malignant lymphoproliferative disease. As the inflammatory process persists, secretory acini undergo progressive atrophy and eventual loss. Ducts become encased in thick bands of fibrous tissue—a process called periductal fibrosis—and the interlobular architecture is gradually replaced by dense connective tissue, producing the characteristic sclerosis. A pivotal modern addition to this histological picture is the identification of abundant IgG4-positive plasma cells within the infiltrate, alongside elevated serum IgG4 concentrations. This immunological signature has reclassified the condition as a manifestation of IgG4-related disease, linking it to a family of morphologically similar fibro-inflammatory lesions observed in other organ systems.

Unraveling the Cause: From Salivary Stones to IgG4-Related Disease

The precise origin of chronic sclerosing sialadenitis remains incompletely elucidated, and several contributing mechanisms have been proposed over the years. One long-standing hypothesis implicates sialolithiasis—the deposition of calcium-salt calculi within salivary ducts—as a primary trigger, since stones are identified in a notable proportion of submandibular cases, though their absence in many instances weakens this explanation. Ductal structural abnormalities causing retention of secretions and subsequent chronic irritation represent another plausible pathway. The immune-driven hypothesis, however, has gained the strongest support in recent decades. The overwhelming infiltration of lymphoid cells and fibrous tissue, combined with the discovery of IgG4-positive plasma cells and raised serum IgG4 levels, has led researchers to reclassify the condition within the broader IgG4-related disease spectrum. This reclassification is reinforced by the observation of histologically and immunohistochemically identical lesions in other body sites. The condition predominantly affects adults between 40 and 70 years of age, although a rare case with prominent immunopathological features was documented in an 11-year-old boy in Brazil in 2012.

From the Operating Room to the Steroid Vial: Evolving Treatment Strategies

For decades, the definitive management of chronic sclerosing sialadenitis has been surgical removal of the affected gland, either partially or entirely, a procedure known as sialoadenectomy. Because the condition is clinically indistinguishable from malignancy, surgery is typically performed on the suspicion of cancer, and the benign diagnosis is confirmed only in the post-operative histopathology report. The procedure carries relatively low operative morbidity, making it a straightforward intervention once the decision to operate is made. In more recent years, however, a less invasive alternative has gained favor: systemic corticosteroid therapy. Steroids have been shown to shrink the inflammatory mass and reduce serum IgG4 levels, offering a viable option for younger patients or those who decline surgery. This therapeutic shift reflects the broader recognition of the condition as an IgG4-related inflammatory process rather than a purely structural problem. Despite these advances, the condition remains under-recognized, and many patients still undergo unnecessary surgery before the correct diagnosis is made, underscoring the ongoing need for improved pre-operative tools such as ultrasonography and fine-needle aspiration cytology.